Addition of eGFR and age improves the prognostic absolute renal risk-model in 1,134 norwegian patients with IgA nephropathy

American Journal of Nephrology

Volumn 41, Issue 3, 2015, Pages 210-219

  Knoop, Thomas ^a,b   Vågane, Ann Merethe ^a   Vikse, Bjørn Egil ^a,c   Svarstad, Einar ^a,b   Magnúsdóttir, Bergrún Tinna ^d   Leh, Sabine ^a,b   Varberg Reisæter, Anna ^e   Bjørneklett, Rune ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b Haukeland University   (Norway)

^c HAUGESUND HOSPITAL   (Norway)

^d HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY OF OSLO   (Norway)

Author keywords

End stage renal disease; Immunoglobulin A nephropathy; Mortality; Prognosis; Risk factor

Indexed keywords

ABSOLUTE RENAL RISK MODEL; ADULT; AGE; AREA UNDER THE CURVE; ARTICLE; DEATH; END STAGE RENAL DISEASE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTENSION; IMMUNOGLOBULIN A NEPHROPATHY; MAJOR CLINICAL STUDY; MALE; NORWEGIAN (PEOPLE); PREDICTION; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; PROTEINURIA; RISK ASSESSMENT; RISK FACTOR; VALIDATION STUDY; AGED; BLOOD; DISEASE COURSE; KIDNEY; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; MORTALITY; NORWAY; PATHOLOGY; PATHOPHYSIOLOGY; PROGNOSIS; TIME FACTOR;

ADULT; AGE FACTORS; AGED; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GLOMERULONEPHRITIS, IGA; HUMANS; HYPERTENSION; KIDNEY; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NORWAY; PROGNOSIS; PROTEINURIA; RISK FACTORS; TIME FACTORS;

EID: 84927936494     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000381403     Document Type: Article

References (23)

1. D'Amico G: The commonest glomerulonephritis in the world: IgA nephropathy. Q J Med 1987; 64: 709-727.
2. Floege J, Feehally J: IgA nephropathy: recent developments. J Am Soc Nephrol 2000; 11: 2395-2403.
3. Levy M, Berger J: Worldwide perspective of IgA nephropathy. Am J Kidney Dis 1988; 12: 340-347.
4. Barbour SJ, Reich HN: Risk stratification of patients with IgA nephropathy. Am J Kidney Dis 2012; 59: 865-873.
5. Canetta PA, Kiryluk K, Appel GB: Glomerular diseases: emerging tests and therapies for IgA nephropathy. Clin J Am Soc Nephrol 2014; 9: 617-625.
6. Wyatt RJ, Julian BA: IgA nephropathy. N Engl J Med 2013; 368: 2402-2414.
7. Alamartine E, Sabatier JC, Guerin C, Berliet JM, Berthoux F: Prognostic factors in mesangial IgA glomerulonephritis: an extensive study with univariate and multivariate analyses. Am J Kidney Dis 1991; 18: 12-19.
8. Chacko B, John GT, Neelakantan N, et al: Presentation, prognosis and outcome of IgA nephropathy in Indian adults. Nephrology (Carlton) 2005; 10: 496-503.
9. D'Amico G: Influence of clinical and histological features on actuarial renal survival in adult patients with idiopathic IgA nephropathy, membranous nephropathy, and membranoproliferative glomerulonephritis: survey of the recent literature. Am J Kidney Dis 1992; 20: 315-323.
10. D'Amico G: Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors. Am J Kidney Dis 2000; 36: 227-237.
11. Donadio JV, Grande JP: IgA nephropathy. N Engl J Med 2002; 347: 738-748.
12. Geddes CC, Rauta V, Gronhagen-Riska C, et al: A tricontinental view of IgA nephropathy. Nephrol Dial Transplant 2003; 18: 1541-1548.
13. Johnson ES, Thorp ML, Yang X, Charansonney OL, Smith DH: Predicting renal replacement therapy and mortality in CKD. Am J Kidney Dis 2007; 50: 559-565.
14. Berthoux F, Mohey H, Laurent B, Mariat C, Afiani A, Thibaudin L: Predicting the risk for dialysis or death in IgA nephropathy. J Am Soc Nephrol 2011; 22: 752-761.
15. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305.
16. Tripepi G, Heinze G, Jager KJ, Stel VS, Dekker FW, Zoccali C: Risk prediction models. Nephrol Dial Transplant 2013; 28: 1975-1980.
17. Goto M, Wakai K, Kawamura T, Ando M, Endoh M, Tomino Y: A scoring system to predict renal outcome in IgA nephropathy: a nationwide 10-year prospective cohort study. Nephrol Dial Transplant 2009; 24: 3068-3074.
18. Churg J : IgA nephropathy; in Glassock R (ed): Renal Disease-Classification and Atlas of Glomerular Diseases, ed 2. New York, Tokyo, IGAKU-SHOIN, 1995, p 181.
19. Wakai K, Kawamura T, Endoh M, et al: A scoring system to predict renal outcome in IgA nephropathy: from a nationwide prospective study. Nephrol Dial Transplant 2006; 21: 2800-2808.
20. Bjørneklett R, Vikse BE, Bostad L, Leivestad T, Iversen BM: Long-term risk of ESRD in IgAN; validation of Japanese prognostic model in a Norwegian cohort. Nephrol Dial Transplant 2012; 27: 1485-1491.
21. Knoop T, Vikse BE, Svarstad E, Leh S, Reisæter AV, Bjørneklett R: Mortality in patients with IgA nephropathy. Am J Kidney Dis 2013; 62: 883-890.
22. Mohey H, Laurent B, Mariat C, Berthoux F: Validation of the absolute renal risk of dialysis/death in adults with IgA nephropathy secondary to Henoch-Schönlein purpura: a monocentric cohort study. BMC Nephrol 2013; 14: 169.
23. Cattran DC, Coppo R, Cook HT, et al: The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int 2009; 76: 534-545.